| Page 1934 | Kisaco Research
 

Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment

Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment

Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment
 

Dr David Sourdive

Executive Vice President Technical Operations
Cellectis

Dr David Sourdive

Executive Vice President Technical Operations
Cellectis

Dr David Sourdive

Executive Vice President Technical Operations
Cellectis
 

Stefano Baila

Former Process Development Manager
Holding F.I.S.

Stefano Baila

Former Process Development Manager
Holding F.I.S.

Stefano Baila

Former Process Development Manager
Holding F.I.S.
 

Michaela Sharpe

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell & Gene Therapy Catapult

Michaela Sharpe

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell & Gene Therapy Catapult

Michaela Sharpe

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell & Gene Therapy Catapult
 

Sarah Snykers

QC Manager
Celyad

Sarah Snykers

QC Manager
Celyad

Sarah Snykers

QC Manager
Celyad
 

Michaela Sharpe

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell & Gene Therapy Catapult

Michaela Sharpe

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell & Gene Therapy Catapult

Michaela Sharpe

Head of Non-Clinical Safety and Immunotherapy Strategy
Cell & Gene Therapy Catapult
 

Mark Aspinall O’Dea

EMEA Business Development Manager
Retogenix

Mark Aspinall O’Dea

EMEA Business Development Manager
Retogenix

Mark Aspinall O’Dea

EMEA Business Development Manager
Retogenix
 
26-27 Feb 2019
200 Aldersgate, St. Pauls, London, UK
Animal Health Investment Europe is a premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition and connecting those businesses with financial investors and strategic corporate partners. To complement our investment pitches, we host CEO-level discussions that address the trends and market dynamics of the animal health industry, across all species. A key element of the investment forum is the full use of a our 1-on-1 private meeting platform, available to all attendees. Going forward, as the industry experiences a shift towards the detection and prevention of disease, we are increasingly focused on presenting innovation in nutritional health, data analytics, sensors and diagnostics.This year, for the first time, we will be categorising our presenting companies according to the level of investment they’re seeking, early, mid and late stage.
Agenda from Human Biotech & Animal Health USA 2018
 
Human Biotech Animal Health EU
18-19 Jun 2018
Amsterdam, The Netherlands
Join the first ever conference series connecting human biotechs with the animal health industry. Following the event's hugely successful launch in Boston, USA, Human Biotech & Animal Health Business Partnering Summit is now coming to Europe. Traditionally, innovation in veterinary health has come from parent human pharmaceutical R&D pipelines. Within an increasingly independent and mature animal health industry, new routes to innovation are being established. There are a multitude of exceptional technologies in the human health field that could be used in animal health, but currently there is limited contact between the two areas – this summit aims to connect the two industries.